Evidence map›Paper›PMID 19875605›Full record

ArticleDiabetes care2009

Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.

Michael J Haller, Clive H Wasserfall, Kieran M McGrail, Miriam Cintron, Todd M Brusko, John R Wingard, Susan S Kelly, Jonathan J Shuster, Mark A Atkinson, Desmond A Schatz

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00305344 (Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00305344 phase1 / phase2completednot on this map

Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study

TypeinterventionalSponsorUniversity of FloridaRan2005 to 2011Enrolled23ConditionsType 1 Diabetes MellitusArmsAutologous Umbilical Cord Blood Transfusion, Cord blood
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013
    Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Progress in immune-based therapies for type 1 diabetes.Clinical and experimental immunology · 2013
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michael J HallerDepartment of Pediatrics, The University of Florida, Gainesville, Florida, USA. hallemj@peds.ufl.edu
Clive H Wasserfall
Kieran M McGrail
Miriam Cintron
Todd M Brusko
John R Wingard
Susan S Kelly
Jonathan J Shuster
Mark A Atkinson
Desmond A Schatz
University of Florida · USUniversity of California, San Francisco · USUniversity of Houston · US

Funding

WHITE MATTER AND COGNITION IN PARKINSON'S DISEASEM01RR000082 · NCRR · UNIVERSITY OF FLORIDA · PI FOOTE, KELLY D · 1985 to 2009
$29.7M
Cord Blood Immunoregulation of Type 1 DiabetesR21DK077580 · NIDDK · UNIVERSITY OF FLORIDA · PI ATKINSON, MARK A. · 2006 to 2007
$388k
NCRR NIH HHS M01 RR000082NCRR NIH HHS M01RR00082NIDDK NIH HHS 1R21DK077580-01NIDDK NIH HHS R21 DK077580
6 · The paper itself

Abstract

objectiveInterest continues to grow regarding the therapeutic potential for umbilical cord blood therapies to modulate autoimmune disease. We conducted an open-label phase I study using autologous umbilical cord blood infusion to ameliorate type 1 diabetes. RESEARCH DESIGN AND

methodsFifteen patients diagnosed with type 1 diabetes and for whom autologous umbilical cord blood was stored underwent a single intravenous infusion of autologous cells and completed 1 year of postinfusion follow-up. Intensive insulin regimens were used to optimize glycemic control. Metabolic and immunologic assessments were performed before infusion and at established time periods thereafter.

resultsMedian (interquartile range [IQR]) age at infusion was 5.25 (3.1-7.3) years, with a median postdiagnosis time to infusion of 17.7 (10.9-26.5) weeks. No infusion-related adverse events were observed. Metabolic indexes 1 year postinfusion were peak C-peptide median 0.50 ng/ml (IQR 0.26-1.30), P = 0.002; A1C 7.0% (IQR 6.5-7.7), P = 0.97; and insulin dose 0.67 units * kg(-1) * day(-1) (IQR 0.55-0.77), P = 0.009. One year postinfusion, no changes were observed in autoantibody titers, regulatory T-cell numbers, CD4-to-CD8 ratio, or other T-cell phenotypes.

conclusionsAutologous umbilical cord blood transfusion in children with type 1 diabetes is safe but has yet to demonstrate efficacy in preserving C-peptide. Larger randomized studies as well as 2-year postinfusion follow-up of this cohort are needed to determine whether autologous cord blood-based approaches can be used to slow the decline of endogenous insulin production in children with type 1 diabetes.

Indexed as

Blood GlucoseBlood Transfusion, AutologousCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChildChild, PreschoolC-PeptideDiabetes Mellitus, Type 1Fetal BloodFollow-Up StudiesGlycated HemoglobinHumansHypoglycemic AgentsInfantInfusions, IntravenousInsulinBlood GlucoseC-PeptideGlycated HemoglobinHypoglycemic AgentsInsulin

Identifiers

PMID19875605
PMCPMC2768209
OpenAlexW2115646569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.